D Williams-Herman

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. doi Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
    D Williams-Herman
    Merck Research Laboratories, Rahway, NJ 07065, USA debora
    Diabetes Obes Metab 12:442-51. 2010
  2. doi Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes
    D Williams-Herman
    Department of Clinical Research, Merck Sharp and Dohme Corp, Rahway, NJ 07065, USA
    Diabetes Obes Metab 14:67-76. 2012
  3. doi Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement
    M Alba
    Merck Research Laboratories, RY34 A244, 126 E Lincoln Ave, Rahway, NJ 07065, USA
    Curr Med Res Opin 25:2507-14. 2009
  4. doi Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach
    L Xu
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Diabetes Obes Metab 10:1212-20. 2008
  5. doi Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1
    E M Migoya
    Merck Research Laboratories, Rahway, New Jersey, USA
    Clin Pharmacol Ther 88:801-8. 2010

Collaborators

  • M J Davies
  • B Charbonnel
  • M Alba
  • J J Holst
  • E M Migoya
  • L Xu
  • R N K Snyder
  • M Gutierrez
  • P Larson
  • J Amatruda
  • J A Wagner
  • G Jiang
  • M Tanen
  • F Liu
  • R SinhaRoy
  • C Deacon
  • R Bergeron
  • N Thornberry
  • D Hilliard
  • K A Pryor
  • G Herman
  • L Zhu
  • J L Miller
  • B Weiss
  • J Yao
  • P P Stein
  • G Meninger
  • C Dalla Man
  • C Cobelli

Detail Information

Publications5

  1. doi Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
    D Williams-Herman
    Merck Research Laboratories, Rahway, NJ 07065, USA debora
    Diabetes Obes Metab 12:442-51. 2010
    ..To assess the 104-week efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes and inadequate glycaemic control (HbA(1c) 7.5-11%) on diet and exercise...
  2. doi Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes
    D Williams-Herman
    Department of Clinical Research, Merck Sharp and Dohme Corp, Rahway, NJ 07065, USA
    Diabetes Obes Metab 14:67-76. 2012
    ..To examine the effect of sitagliptin and metformin, alone and in combination, on modelled parameters of β-cell function in patients with type 2 diabetes...
  3. doi Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement
    M Alba
    Merck Research Laboratories, RY34 A244, 126 E Lincoln Ave, Rahway, NJ 07065, USA
    Curr Med Res Opin 25:2507-14. 2009
    ....
  4. doi Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach
    L Xu
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Diabetes Obes Metab 10:1212-20. 2008
    ..The purpose of this exploratory analysis was to assess the effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on pancreatic beta-cell function using a model-based analysis...
  5. doi Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1
    E M Migoya
    Merck Research Laboratories, Rahway, New Jersey, USA
    Clin Pharmacol Ther 88:801-8. 2010
    ..DPP-4 inhibitors and metformin have complementary mechanisms of action and additive effects with respect to increasing the concentrations of active GLP-1 in plasma...